Regulatory reference

Exosome Clinical Trials: What the Registry Shows

Reviewed by ExaVeyra Sciences editorial team · Updated 17 August 2026

Asked how many exosome clinical trials exist, the honest answer is that it depends entirely on what you are willing to call one. Searching ClinicalTrials.gov for the word returns one number, scoping that search to the intervention returns a smaller one, and checking that an intervention is actually an exosome returns smaller again. This page gives all three, explains the gap, and sets out what the registry shows about the field as of 2026-08-17.

It also states the thing a registry cannot: none of this is evidence that anything works. A trial registration is a filing that records a study exists. It is made before results, often before the first participant, and it carries no finding of any kind.

Three counts, all defensible

A keyword search of the registry returns studies that merely mention exosomes, which includes trials where exosomes are a laboratory readout rather than the thing being given. The first interventional result for that search, at the time of writing, was a pregnancy weight-loss study whose only intervention was behavioural. Scoping to the intervention field removes most of that, and still admits studies whose listed interventions are stem cells, or in one case moxibustion. Counting only studies where an intervention is named as an exosome or extracellular vesicle gives 133.

The field is early, small and academic

Of the 133 studies counted, 76 are phase 1 or early phase 1 and 9 are phase 3 or 4. Median enrolment is 30 participants, and the largest single study plans 300. Those two facts together describe a field that is establishing safety and feasibility rather than one that is confirming effect.

Sponsorship tells the same story from another direction. 109 of the studies are led by the registry's "other" class, which is overwhelmingly universities and hospitals, against 15 led by industry. A field with commercial programmes approaching approval usually looks the other way round.

Where the trials are concentrated

Grouping by indication uses keyword matching over the registry's free-text condition strings, which are not a controlled vocabulary: the same disease appears several ways and some entries list a cell type where a condition belongs. The groups below are therefore approximate, and anything matching none of them is reported rather than absorbed.

Dermatology and aesthetics being the largest group is worth pausing on, because it is also the area where marketing claims run furthest ahead of published outcomes. A concentration of registrations in a field is a statement about where interest and investment are, and says nothing about which of those studies will report a positive result, or report at all.

What a registration does and does not mean

Registration of an applicable clinical trial is required by law, not granted as a privilege. Under 42 CFR 11.24 the responsible party must submit registration information no later than 21 calendar days after the first participant is enrolled, and under 42 CFR 11.44 results information is generally due within one year of the primary completion date. A registration therefore records that someone started a study and told the registry, which is a legal obligation discharged rather than a scientific finding.

• A registration is not FDA approval, clearance, or any determination that a product is safe or effective.
• A registration is not peer review. Nobody assesses the science before an entry appears.
• An active or recruiting status means a study is under way, not that early results are promising.
• A completed status does not mean results were published, or even posted to the registry.
• An NCT number in marketing material tells you a study exists. It does not tell you what it found.

This matters specifically for exosome products because FDA has been explicit that they fall outside the 361 HCT/P pathway, which is set out on our page comparing 361 HCT/Ps with 351 biologics. A trial registration does not create a lawful marketing route, and an investigational product remains investigational.

Reading an entry yourself

Everything on this page came from a public API that anyone can query, and checking a specific claim takes a couple of minutes. Given an NCT number, open the record and read four fields before anything else.

• Study type. Interventional means something was given. Observational means it was watched.
• Interventions. Read the names, not the title. A study titled around exosomes may list stem cells, or a device, or nothing relevant.
• Enrolment and phase together. Twenty participants in a phase 1 is a safety study, whatever the condition studied.
• Status and last update. An unknown status past its completion date means the sponsor stopped maintaining the record.

This page describes the contents of a public trial registry as of the date shown. It is not medical advice, not a claim that any product is safe or effective, and not an offer to sell any investigational product. ExaVeyra Sciences supplies research-use-only material to licensed practitioners and does not hold an investigational new drug application for any product described here.

Sources

1. ClinicalTrials.gov, search of interventional studies (accessed 17 August 2026)
2. ClinicalTrials.gov API v2 documentation (accessed 17 August 2026)
3. 42 CFR 11.24, when must registration information be submitted (accessed 17 August 2026)
4. 42 CFR 11.44, when must results information be submitted (accessed 17 August 2026)
5. FDA, Public Safety Notification on Exosome Products (accessed 17 August 2026)